Evidence map›Paper›PMID 33677681›Full record

ReviewThe AAPS journal2021

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.

Julianne D Twomey, Baolin Zhang

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The AAPS journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 402 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
402citing papers in PubMed, 6 pooled it
46.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

402 citing papers in PubMed, 6 syntheses or guidelines pooled it, 648 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Sex Steroid Hormone Regulation of T-Cell Function and Antitumor Immunity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

342 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Julianne D TwomeyOffice of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, 20993, USA. Julianne.Twomey@fda.hhs.gov.
Baolin ZhangOffice of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, 20993, USA. Baolin.zhang@fda.hhs.gov.
Center for Drug Evaluation and Research · US

Funding

FDA HHS
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that target the programmed cell death 1 (PD-1) or its ligand, PD-1 ligand 1 (PD-L1), including information on their clinical indications and associated companion diagnostics. The information is further discussed with strategies for identifying predictive biomarkers to guide the clinical use of PD-1/PD-L1-targeted therapies.

Indexed as

Reagent Kits, DiagnosticB7-H1 AntigenBiomarkers, TumorClinical Decision-MakingDiagnostic Test ApprovalDrug ApprovalHumansImmune Checkpoint InhibitorsNeoplasmsProgrammed Cell Death 1 ReceptorUnited StatesUnited States Food and Drug AdministrationB7-H1 AntigenBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReagent Kits, Diagnosticbiomarkercancer immunotherapycompanion diagnosticimmune checkpoint inhibitor

Identifiers

PMID33677681
PMCPMC7937597
OpenAlexW3134655285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.